OUR LEADERSHIP TEAM, BOARD MEMBERS AND ADVISORS ARE CANCER IMMUNOLOGISTS, DRUG DEVELOPERS AND COMPANY BUILDERS WITH EXTENSIVE INDUSTRY EXPERIENCE. AS A TEAM, WE ARE LEVERAGING OUR DIVERSE EXPERTISE AND PASSION FOR INNOVATION TO BUILD A SUSTAINABLE COMPANY AND FIND CURES FOR CANCER PATIENTS.
Garry Menzel, PhD and MBA
CHIEF EXECUTIVE OFFICER
Dr. Menzel joined TCR2 in 2016 as a Director and Chief Executive Officer. He has over 20 years of experience in building healthcare businesses and leading high-performing teams of professionals. He has also led multiple corporate transactions, including private financings, initial public offerings, licensing and M&A. Prior to TCR2, he was the Chief Strategy Officer at Axcella Health, the Chief Financial Officer at DaVita Healthcare (NYSE: DVA), and the Chief Operating Officer at Regulus Therapeutics (NASDAQ:RGLS). Dr. Menzel also had global leadership roles in running the biotechnology practices at Goldman Sachs and Credit Suisse. In addition, he was a consultant with Bain & Company. Dr. Menzel earned his PhD from the University of Cambridge for studying the regulation of oncogenes in immune cells. He also has a MBA from the Stanford Graduate School of Business.
Robert Hofmeister, PhD
CHIEF SCIENTIFIC OFFICER
Dr. Hofmeister joined TCR2 in 2015 as the company’s first employee. He brings nearly two decades of scientific leadership and a successful track record of drug discovery and early development. Previously, Dr. Hofmeister was the Vice President of Immuno-Oncology at EMD Serono where he was involved in the development of now approved Bavencio® (avelumab) and building the company’s immuno-oncology platform. He started his biotech career at Micromet AG, now Amgen Research Munich, where he helped shape the development of Blincyto®, the first FDA-approved bispecific antibody for the treatment of relapsed/refractory ALL. Dr. Hofmeister received his PhD from the University of Regensburg in Germany, where he studied the signaling of the cytokine interleukin-1. He continued to work in the cytokine field as a postdoctoral fellow at the National Cancer Institute.
Alfonso Quintás Cardama, MD
CHIEF MEDICAL OFFICER
Dr. Quintás joined TCR2 in 2017 as Chief Medical Officer. He brings nearly two decades of experience leading clinical strategy and regulatory filings for multiple oncology therapeutics resulting in market approval. Dr. Quintás was the clinical development head of the Cell & Gene Therapies Unit at GlaxoSmithKline where he was responsible for the full clinical development strategy, execution and collaboration with Adaptimmune on affinity enhanced T-cell therapies. Previously, he served as Global Clinical Leader of Novartis’ now approved Kymriah™ (tisagenlecleucel) CTL019 program and was an Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center. Dr. Quintás earned his MD from the Universidad de Santiago de Compostela School of Medicine in Spain. He completed an internship and residency in the Department of Medicine, Albert Einstein College of Medicine in New York and a Hematology and Oncology fellowship at The University of Texas, MD Anderson Cancer Center.
Andrew Cornforth, PhD
VICE PRESIDENT OF PROCESS DEVELOPMENT
Dr. Cornforth joined TCR2 in 2017 as Vice President of Process Development. He brings over 20 years of cell therapy experience having led process development and manufacturing of multiple cell therapy programs from preclinical through late-stage clinical development. Dr. Cornforth was the Vice President of Manufacturing at AIVITA Biomedical and Director of Manufacturing at Progenitor Cell Therapy where his broad expertise was applied to the development of T cells, dendritic cells and stem cells. He has manufactured patient cell-derived immunotherapies for more than 200 patients. Dr. Cornforth earned his BS in Chemistry and PhD from the University of California at Irvine where he studied cell signaling in prostate cancer apoptosis.
Daniel Getts, PhD and MBA
VICE PRESIDENT OF RESEARCH
Dr. Getts joined TCR2 in 2017 as Vice President of Research, responsible for target discovery, preclinical research and translational sciences. Previously, he was co-inventor, co-founder and Chief Scientific Officer of Cour Pharmaceuticals, a nanotechnology company focused on immune disorders. He also served as Director, Research & Development at Tolera Therapeutics where he was responsible for advancing the company’s monoclonal antibody programs. He has managed global research programs, playing a pivotal role in guiding the translation of a number of basic discoveries from the bench to clinical testing. Dr. Getts is widely published and is also the lead inventor on numerous issued patents and more than 30 patent applications. He received his PhD in Medicine from the University of Sydney where he studied immune pathogenesis of disease and therapeutic strategies to modulate it. He also has a MBA from Western Michigan University.
Helen Ho, PhD
HEAD OF CORPORATE DEVELOPMENT
Dr. Ho joined TCR2 in 2016 as Head of Corporate Development. She brings more than 10 years of biopharmaceutical industry experience across a range of strategic and operating roles. Prior to joining TCR2, Dr. Ho was the Director of Business Development & Operations at Agios Pharmaceuticals (NASDAQ: AGIO) where she built and led the company’s licensing function and served as the Business Strategy and Alliance Lead for its Metabolic Immuno-Oncology group. As an early employee of Agios, she was involved in the IPO of the company and building of its Rare Genetic Disorders franchise, including product planning efforts. Prior to Agios, she was a management consultant at L.E.K’s Biopharma & Life Sciences Practice. Dr. Ho earned her BS in Biochemistry from UCLA and PhD in Cell Biology from Yale University School of Medicine.
HEAD OF OPERATIONS & HUMAN RESOURCES
Ms. Lynch joined TCR2 in 2015 at the company’s inception. She brings over 10 years of biopharmaceutical industry experience across a range of operational roles. Prior to joining TCR2, Ms. Lynch was the Associate Director of Operations and Investor Relations/Project Management at Catabasis Pharmaceuticals (NASDAQ: CATB), a rare diseases company where she built out the company infrastructure and helped implement cross-functional areas including IT, HR, facilities, project management and investor relations as one of its first employees. Prior to Catabasis, she was the Biological Services Manager at Sirtris Pharmaceuticals (acquired by GlaxoSmithKline). Ms. Lynch earned her BS in Biochemistry, Cellular, Molecular Biology from Connecticut College.
Gregory Sieczkiewicz, PhD and JD
CHIEF IP COUNSEL
Dr. Sieczkiewicz joined TCR2 in 2015 at the company’s inception to lead its operations. He brings extensive experience in building transformative biotechnology companies at the intersection of business and legal functions. He has over 8 years of venture creation and venture capital financing experience, and over 16 years practicing intellectual property law. Dr. Sieczkiewicz is also a Managing Director and Chief IP Counsel of MPM Capital. Prior to MPM, he was the Vice President of Intellectual Property at Flagship Ventures. He also represented healthcare companies in patent counseling, patent litigation and licensing as an associate attorney at Mintz Levin, Proskauer Rose, and Foley Hoag. Dr. Sieczkiewicz earned his PhD from Tufts University School of Medicine, and completed his postdoctoral fellowship at the National Cancer Institute. He earned his JD from Suffolk University Law School.